Takefumi Komiya, MD, PhD - Penn State Cancer Institute
Researcher Profile
Takefumi Komiya, MD, PhD
Associate Professor, Department of Medicine
Scientific Program:Next-Generation Therapies
Clinical Trials
NRG-CC013: A Randomized, Masked, Placebo Controlled, Phase II Trial Of Concurrent Chemoradiation With Bmx-001 In Patients With Head And Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation
Consolidative Use Of Radiotherapy To Block (Curb2) Oligoprogression In Patients With Metastatic Non-Small-Cell Lung Cancer - A Randomized Phase 3 Trial (BR.38)
Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)
A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery
EA5221: A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable older adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study
Long-term Follow-up of AAV2-hAQP1 Gene Therapy in Participants with Radiation-Induced Late Xerostomia
NRG-LU007 Randomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial
NRG-LU008: Phase III Prospective Randomized Trial Of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed By Concurrent Mediastinal Chemoradiation For Locally Advanced Non-Small Cell Lung Cancer
A randomized phase II trial of adjuvant Pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153
Recent Publications
2025
Hashinokuchi, A, Takamori, S, Takenaka, T, Yoshizumi, T & Komiya, T 2025, 'ASO Author Reflections: Impact of Primary Tumor Size in Thymic Epithelial Tumor', Annals of Surgical Oncology, vol. 32, no. 3, pp. 1683-1684. https://doi.org/10.1245/s10434-024-16827-z
Layng, SC, Betsock, A, Mansouri, A, Komiya, T, Miccio, JA, Mahase, SS & Knisely, JPS 2025, 'Brain metastases from lung cancer: recent advances and novel therapeutic opportunities', Discover Oncology, vol. 16, no. 1, 157. https://doi.org/10.1007/s12672-025-01873-0
azquez-Urrutia, JR, Venugopal, N, Zhu, J, Miccio, JA, Machtay, M & Komiya, T 2025, 'Evaluating the role of consolidative chest radiotherapy after chemo-immunotherapy in extensive-stage small cell lung cancer: a retrospective study', Discover Oncology, vol. 16, no. 1, 813. https://doi.org/10.1007/s12672-025-02589-x
Venugopal, N, Vazquez-Urrutia, JR, Zhu, J, Hashinokuchi, A, Takamori, S & Komiya, T 2025, 'Lack of Survival Benefit with Immunotherapy in Combination with Adjuvant Chemoradiation in Pathologic Stage II-IIIB Non-small Cell Lung Cancer', Annals of Surgical Oncology, vol. 32, no. 10, pp. 7883-7890. https://doi.org/10.1245/s10434-025-17766-z
Hashinokuchi, A, Takamori, S, Takenaka, T, Yoshizumi, T & Komiya, T 2025, 'Narrative review of the prognostic significance of primary tumor size in thymic epithelial tumor', Mediastinum, vol. 9, 14. https://doi.org/10.21037/med-25-3
Komiya, T, Sweeney, K, Huang, CH, Crymes, A, Antonarakis, ES, Elliott, A, Oberley, MJ & Evans, MG 2025, 'Novel MAML2 Fusions in Human Malignancy †', Cancers, vol. 17, no. 19, 3146. https://doi.org/10.3390/cancers17193146
Vazquez-Urrutia, JR, Zhu, J, Takamori, S, Greenberg, M, Bhatia, P & Komiya, T 2025, 'Survival outcomes of surgery and adjuvant chemotherapy in early-stage small cell and large cell lung cancer: a novel focus on tumors less than 1 cm', Discover Oncology, vol. 16, no. 1, 82. https://doi.org/10.1007/s12672-025-01777-z
2024
KEYNOTE-671 Investigators 2024, 'Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet, vol. 404, no. 10459, pp. 1240-1252. https://doi.org/10.1016/S0140-6736(24)01756-2
Hashinokuchi, A, Takamori, S, Zhu, J, Abe, M, Ozono, K, Takenaka, T, Osoegawa, A, Yoshizumi, T & Komiya, T 2025, 'Prognostic Impact of Primary Tumor Size in Thymic Epithelial Tumor: An NCDB-Based Study', Annals of Surgical Oncology, vol. 32, no. 3, e211793, pp. 1662-1669. https://doi.org/10.1245/s10434-024-16732-5
Vazquez-Urrutia, JR, Greenberg, M, Zhu, J, Takamori, S & Komiya, T 2024, 'Prognostic Implications of Timing of Immunotherapy in Stage IV Non-Small Cell Lung Cancer', World Journal of Oncology, vol. 15, no. 5, pp. 769-776. https://doi.org/10.14740/wjon1924
Takamori, S, Osoegawa, A, Hashinokuchi, A, Karashima, T, Takumi, Y, Abe, M, Yamaguchi, M, Takenaka, T, Yoshizumi, T, Zhu, J & Komiya, T 2024, 'Role of Pathologic Single-Nodal and Multiple-Nodal Descriptors in Resected Non-Small Cell Lung Cancer', CHEST, vol. 166, no. 5, pp. 1218-1228. https://doi.org/10.1016/j.chest.2024.06.3797
Takamori, S, Zhu, J, Hashinokuchi, A & Komiya, T 2024, 'The Clinical Role of Adjuvant Chemotherapy after Sublobar Resection for Non-Small-Cell Lung Cancer ≤ 20 mm with Lymph Node Metastases: A Propensity-Matched Analysis of the National Cancer Database', Cancers, vol. 16, no. 12, 2176. https://doi.org/10.3390/cancers16122176
2023
Takamori, S, Shimokawa, M & Komiya, T 2023, 'Efficacy of immune checkpoint inhibitors in younger patients with non-small cell lung cancer', Journal of Cancer Research and Clinical Oncology, vol. 149, no. 14, pp. 13175-13184. https://doi.org/10.1007/s00432-023-05167-2
Khan, SS & Komiya, T 2023, 'Exclusion of Patients with Autoimmune Disease in Lung Cancer Clinical Trials', Asian Pacific Journal of Cancer Prevention, vol. 24, no. 1, pp. 331-336. https://doi.org/10.31557/APJCP.2023.24.1.331
Komiya, T, Takamori, S & Shimokawa, M 2023, 'Impact of Liver Metastasis on First-Line Immunotherapy in Stage IV Non-Small Cell Lung Cancer', World Journal of Oncology, vol. 14, no. 4, pp. 234-245. https://doi.org/10.14740/wjon1625
Takamori, S, Komiya, T, Shimokawa, M & Powell, E 2023, 'Lymph node dissections and survival in sublobar resection of non-small cell lung cancer ≤ 20 mm', General Thoracic and Cardiovascular Surgery, vol. 71, no. 3, pp. 189-197. https://doi.org/10.1007/s11748-022-01876-6
2022
Komiya, T, Takamori, S & Wilding, G 2022, 'Adjuvant radiation therapy improves survival in stage IIIA (N2) non-small cell lung cancer with persistent N2 disease after neoadjuvant chemotherapy', Radiotherapy and Oncology, vol. 176, pp. 234-238. https://doi.org/10.1016/j.radonc.2022.07.018
Sama, S, Komiya, T & Guddati, AK 2022, 'Advances in the Treatment of Mucoepidermoid Carcinoma', World Journal of Oncology, vol. 13, no. 1. https://doi.org/10.14740/wjon1412
Takamori, S, Komiya, T & Powell, E 2022, 'Clinical impact of number of lymph nodes dissected on postoperative survival in node-negative small cell lung cancer', Frontiers in Oncology, vol. 12, 962282. https://doi.org/10.3389/fonc.2022.962282
Dasari, S & Komiya, T 2022, 'Induction Immunotherapy Followed by Thoracic Radiation without Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: A Case Series', Asian Pacific Journal of Cancer Prevention, vol. 23, no. 1, pp. 217-220. https://doi.org/10.31557/APJCP.2022.23.1.217
Komiya, T, Takamori, S & Wilding, G 2022, 'Response to Bao et al', Radiotherapy and Oncology, vol. 177, pp. 251. https://doi.org/10.1016/j.radonc.2022.10.031